Treatment of diabetes mellitus in dialysis patients
- 作者: Bondar' I.1, Klimontov V.1, Bondar I2, Klimontov V2
-
隶属关系:
- ГОУ ВПО Новосибирский государственный медицинский университет
- State Medical University, Novosibirsk
- 期: 卷 83, 编号 12 (2011)
- 页面: 73-77
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30965
- ID: 30965
如何引用文章
全文:
详细
作者简介
Irina Bondar'
ГОУ ВПО Новосибирский государственный медицинский университетпроф. каф. эндокринологии ГОУ ВПО Новосибирский государственный медицинский университет, тел.: (383) 315-99-21; ГОУ ВПО Новосибирский государственный медицинский университет
Vadim Klimontov
ГОУ ВПО Новосибирский государственный медицинский университет
Email: klimontov@mail.ru
д-р мед. наук, доц. каф. эндокринологии НГМУ; ГОУ ВПО Новосибирский государственный медицинский университет
I Bondar
State Medical University, NovosibirskState Medical University, Novosibirsk
V Klimontov
State Medical University, NovosibirskState Medical University, Novosibirsk
参考
- Schemthaner G. Kidney disease in diabetology: lessons from 2007. Nephrol. Dial. Transplant. 2008; 23 (4): 1112-1115.
- Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48 (8): 1439- 1444.
- van Dijk P. С. W., Jager K. J., Stengel B. et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registeries in Europe (1991-2000). Kidney Int. 2005; 67 (4): 1489-1499.
- Бикбов Б. Т., Томилина Н. А. Состояние заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ 2009; 3: 144-219.
- Sechi L. A., Catena С., Zingaro L. et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51 (4): 1226-1232.
- Kobayashi S., Maesato K., Moriya H. et al. Insulin resistance in patients with chronic kidney disease. Am. J. Kidney Dis. 2005; 45 (2): 275-280.
- Charlesworth J. A., Kriketos A. D., Jones J. E. et al. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005; 54 (6): 821-828.
- Rave K., Heise Т., Pfützner A. et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabet. Care 2001; 24 (5): 886-890.
- D'Apolito M., Du X., Zong H. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J. Clin. Invest. 2010; 120 (1): 203-213.
- Бергер М., Старостина Е. Г., Йоргенс В., Дедов И. Практика инсулинотерапии. 1-е рус. изд. Berlin; Heidelberg: Springer-Verlag; 1990.
- Moen M. F., Zhan M., Hsu V. D. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4 (6): 1121-1127.
- Климонтов В. В. Особенности формирования и ранняя диагностика почек у больных сахарным диабетом 1-го типа: Автореф. дис. ... д-ра мед. наук. Новосибирск; 2008.
- Burger A. J., D'Elia J. A., Weinrauch L. A. et al. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy. Int. J. Cardiol. 2002; 86 (2-3): 281- 287.
- Abe M., Kikuchi F., Kaizu K., Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin. Nephrol. 2008; 69 (5): 354-360.
- Abe M., Kaizu K., Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther. Apher. Dial. 2007; 11 (4): 280-287.
- Foss M. C., Gouveia L. M., Moysés Neto M. et al. Effect of hemodialysis on peripheral glucose metabolism of patients with chronic renal failure. Nephron 1996; 73 (1): 48-53.
- Даугирдас Дж. Т., Блэйк П. Дж.., Инг Т. С. Руководство по диализу: Пер. с англ. 3-е изд. М.: Центр диализа; Тверь: ООО Изд-во "Триада"; 2003.
- Шестакова М. В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. - М.: Мед. информ. агентство; 2009.
- Tascona D. J., Morton A. R., Toffelmire Е. В. et al. Adequacy of glycemic control in hemodialysis patients with diabetes. Diabet. Care 2006; 29 (10): 2247-2251.
- Oomichi Т., Emoto M., Tabata T. et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabet. Care 2006; 29 (7): 1496-1500.
- Fukuoka K., Nakao K., Morimoto H. et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008; 13 (4): 278-283.
- Ishimura E., Okuno S., Kono K. et al. Glycemic control and survival of diabetic hemodialysis patients - importance of lower hemoglobin A1C levels. Diabet. Res. Clin. Pract. 2009; 83 (3): 320-326.
- Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleveland. Clin. J. Med. 2009; 76 (11): 649-655.
- Manley H. J., Allcock N. M. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003; 23 (7): 861-865.
- Chiang С. K., Но Т. I., Peng Y. S. et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabet. Care 2007; 30 (1): 3-7.
- Abe M., Kikuchi F., Kaizu K., Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin. Nephrol. 2007; 68 (5): 287-294.
- Brunelli S. M., Thadhani R., Ikizler T. A., Feldman H. I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 2009; 75 (9): 961-968.
- Sobngwi E., Enoru S., Ashuntantang G. et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabet. Care 2010; In press.
- Jackson M. A., Holland M. R., Nicholas J. et al. Hemodialysis-induced hypoglycemia in diabetic patients. Clin. Nephrol. 2000; 54 (1): 30-34.
- Burmeister J. E., Scapini A., da Rosa Miltersteiner D. et al. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol. Dial. Transplant. 2007; 22 (4): 1184-1189.
- Rohrscheib M., Tzamaloukas A. H., Ing T. S. et al. Serum potassium concentration in hyperglycemia of chronic dialysis. Adv. Perit. Dial. 2005; 21: 102-105.
- Cho K. H., Do J. Y., Park J. W., Yoon K. W. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients. Nephrol. Dial. Transplant. 2010; 25 (2): 593-599.
- Gallieni M., Musetti C., Granata A. et al. Metabolic consequences of peritoneal dialysis treatment. Panminerva Med. 2009; 51 (3): 175-185.
- Johnson D. W., Armstrong K., Campbell S. B. et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007; 12 (4): 391-398.
- Szeto C. C., Chow K. M., Kwan В. С. et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am. J. Kidney Dis. 2007; 49 (4): 524-532.
- Szeto C. C., Chow K. M, Leung С. В. et al. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol. Dial. Transplant. 2007; 22 (6): 1697-1702.
- Babazono Т., Nakamoto H., Kasai K. et al. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am. J. Nephrol. 2007; 27 (4): 409-415.
- Paniagua R., Ventura M. D., Avila-Däz M. et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit. Dial. Int. 2009; 29 (4): 422-432.
- Lin S. H., Lin Y. F., Kuo S. W. et al. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am. J. Kidney Dis. 2003; 42 (4): 774-780.
- Wong T. Y., Szeto С. С., Chow K. М. et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am. J. Kidney Dis. 2005; 46 (4): 713-719.
- van Hooland S., Boey O., van der Niepen P. et al. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients. Perit. Dial. Int. 2009; 29 (1): 108-111.
- Dasgupta M. K. Strategies for managing diabetic patients on peritoneal dialysis. Adv. Perit. Dial. 2004; 20: 200-202.
- Mehmet S., Quan G., Thomas S., Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis. Diabet. Med. 2001; 18 (8): 679-682.
- Williams J. D., Craig K. J., Topley N. et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 2002; 13: 470-479.
- Stoenoiu M. S., De Vriese A. S., Brouet A. et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int. 2002: 62 (2): 668-678.
- De Vriese A. S., Flyvbjerg A., Mortier S. et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J. Am. Soc. Nephrol. 2003; 14 (8): 2109-2118.
- Selgas R., Diez J. J., Munoz J. et al. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv. Perit. Dial. 1989; 5: 181- 184.
- Tzamaloukas A. H., Oreopoulos D. G. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv. Perit. Dial. 1991; 7: 81-85.
- Nevalainen P., Lahtela J. Т., Mustonen J., Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol. Dial. Transplant. 1997; 12 (1): 145-150.
- Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J. Am. Soc. Nephrol. 2002; 13 (Suppl. 1): S92-S96.
- Wideroe Т. E., Dahl K. J., Smeby L. С et al. Pharmacokinetics of transperitoneal insulin transport. Nephron 1996; 74 (2): 283-290.
- Wanless I. R., Bargman J. M., Oreopoulos D. G. et al. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod. Pathol. 1989; 2: 69-74.
- Torun D., Oguzkurt L., Sezer S. et al. Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients. Perit. Dial. Int. 2005; 25 (6): 596-600.
- Nevalainen P. I., Kallio Т., Lahtela J. T. et al. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin. Perit. Dial. Int. 2000; 20 (6): 637-642.
- Demir S., Torun D., Tokmak N. et al. Resolution of hepatic subcapsular steatosis after discontinuation of CAPD. Nephrol. Dial. Transplant. 2007; 22 (4): 1247-1249.